Welcome to Chiesi
SVERIGE
Stockholm, 6 November 2023 – Chiesi, an international research-focused biopharmaceutical group, announce today its collaboration with SweDeliver, a distinguished research and competence center specializing in drug delivery. This partnership represents a step forward in the pursuit of innovative drug delivery solutions that address the complex challenges faced by patients worldwide.
Chiesi is deeply committed to developing medications that target three critical areas: respiratory diseases, rare/ultra-rare diseases, and specialty care. In fulfilling this commitment, a diverse range of new therapeutics and dosage forms must undergo rigorous research and development. Often, challenges related to the efficient delivery of drugs at the desired target cannot be solved by conventional technologies. More sophisticated strategies are necessary, necessitating advanced research to understand physiological and technological barriers. A scientifically-sound design of drug delivery platforms is imperative.
A Powerful Alliance Driving Advanced Medications to Patients in Need
Mark Parry-Billings, Head of Global Drug Development at Chiesi Group and Site Head of the company’s R&D site in Stockholm, emphasized the importance of this collaboration: "Chiesi believes that the goals of the SweDeliver Center align perfectly with our needs and the synergistic approach will be leveraged with our Global Technical Development team. Indeed, the active research projects undertaken by SweDeliver resonate with the drug delivery challenges faced by Chiesi's pipeline and indeed by the industry. We are confident that SweDeliver can significantly contribute to making advanced therapeutics available to patients in need."
SweDeliver: Bridging Expertise for Drug Delivery with Chiesi
SweDeliver's approach mirrors Chiesi's dedication to innovation. By combining expertise from academia with insights from biotech and pharma companies, SweDeliver provides a platform for advanced research. This collaboration will facilitate the development of cutting-edge drug delivery methods, ensuring that patients receive treatments that are both effective and accessible.
“I am very happy to welcome Chiesi to Swedeliver. As a company committed to innovate pharmaceutical product development, Chiesi is a highly relevant addition to the existing group of companies, and will further strengthen research in SweDeliver of benfit for better medicines to patients”, said Dr. Bertil Abrahamsson, center Board Chairman at SweDeliver.
“That Chiesi choose to join SweDeliver is a further quality stamp for the research and training that we provide within the center. We are excited to start the collaboration with Chiesi and to expand our international network. Chiesi will be an important player for us in our strive to set Europe in pole position within drug delivery”, said Christel Bergström, Center Director at SweDeliver.
Chiesi's partnership with SweDeliver signifies a shared vision for the future of healthcare: one where scientific advancements and collaborative efforts pave the way for groundbreaking medications. Together, Chiesi and SweDeliver are poised to make a lasting impact on patients' lives, ushering in a new era of advanced medications and improved outcomes.
About SweDeliver
SweDeliver is a world leading research and competence centre in Drug Delivery. Many novel molecules in the drug discovery and development pipeline are biological compounds such as proteins, peptides and RNA. These display problems of poor solubility, membrane permeability and low bioavailability. Thus, the Drug Delivery area is today facing tremendous challenges to develop new drug therapies.
SweDeliver was established in response to these challenges. Based on a multi-disciplinary collaboration between academia and industry with financial support from Vinnova (Sweden’s Innovation Agency), the Faculty of Pharmacy at Uppsala University is the academic hub of the Centre with 17 industrial partners contributing expertise and research infrastructure as well as industrial perspectives and needs within the three main research areas of the Centre.
About Chiesi
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we're part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group's research and development centre in Parma works alongside 7 other important R&D hubs in France, the US, Canada, China, the UK, Ireland and Sweden. Chiesi's Swedish research facility, situated in Solna, specializes in biological development and translational and precision medicine.
479-2023-MARK
For further information, please contact:
Chiesi Nordic
Annelie Barkelund
Ext. communications manager
Tel: 072 703 23 86
Email: a.barkelund@chiesi.com
